% | $
Quotes you view appear here for quick access.


  • elk_1l elk_1l Apr 9, 2013 1:13 PM Flag

    Advanced Cell Technology, Cytomedix and Mesoblast to Provide Corporate and Clinical Updates at Regen Med Investor Day

    Alliance for Regenerative Medicine Announces Final Disease Session Panelists; 16 leading regenerative medicine companies discuss late stage and commercial products -

    By Alliance for Regenerative Medicine

    WASHINGTON, APRIL 9, 2013 — /PRNewswire/ -- At the first annual Regen Med Investor Day, Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), Cytomedix, Inc. (OTCQX: CMXI) and Mesoblast Limited will be just three of the 16 leading regenerative medicine companies providing updates on recent corporate and clinical milestones. The Alliance for Regenerative Medicine also announced today that the final panelists have been determined for the three disease sessions which will focus on cardiovascular disease, wound healing and tissue engineering and CNS diseases. The Regen Med Investor Day is the first investor event organized specifically for the regenerative medicine sector and will take place next Wednesday, April 17 at the Harmonie Club, 4 East 60th Street, New York, NY.
    Presentation Highlights In addition to the three companies featured below, the program will include presentations by: Aastrom, Asterias, Athersys, Cytori, Juventas, MiMedx, NeoStem, Organogenesis, Organovo, Pluristem, Sangamo, StemCells, Inc. and Tigenix.

    About the Alliance for Regenerative Medicine

    The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies